Michael Shiekh
Psychiatry · Dallas, TXNPI 1386863397
Payments from drug & device makers
Across 105 payments — averaging $1572.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$109K
- AbbVie$55K
- Johnson & Johnson$394
- Takeda Pharmaceuticals U.S.A., Inc.$182
- Otsuka America Pharmaceutical, Inc.$152
- Sunovion Pharmaceuticals Inc.$150
- plus $508 from 11 others
What the payments were for
- Food & beverage$1,560100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 19 | $108,794 |
| AbbVie(2 entities) | 21 | $54,975 |
| Johnson & Johnson | 15 | $394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $182 |
| Otsuka America Pharmaceutical, Inc. | 8 | $152 |
| Sunovion Pharmaceuticals Inc. | 8 | $150 |
| MDD US Operations, LLC | 1 | $105 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Eisai Inc. | 3 | $58 |
| Noven Therapeutics, LLC | 3 | $56 |
| Almatica Pharma LLC | 3 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Shire North American Group Inc | 1 | $22 |
| Corium, LLC | 2 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Novo Nordisk | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$134
- Lucemyra/Lofexidine$105
How this compares
$165,154 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $1,522 |
| Gabapentin | 12 | $602 |
| Escitalopram Oxalate | 29 | $466 |
| Bupropion XlBupropion Hcl | 19 | $240 |
| Clonazepam | 33 | $239 |
| Trazodone Hcl | 23 | $234 |
| Alprazolam ErAlprazolam | 16 | $210 |
| Alprazolam | 35 | $199 |
| Duloxetine Hcl | 16 | $125 |
| Diazepam | 16 | $84 |
| Lamotrigine | 11 | $73 |
| Zolpidem Tartrate ErZolpidem Tartrate | 12 | $43 |
| Temazepam | 12 | $23 |
| Amitriptyline Hcl | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Dallas
- Scott BartleyDallas$42.7M
- Darin OkudaDallas$14.7M
- Michael DowningDallas$7.6M
- John PascoeDallas$2.3M
- Madhukar TrivediDallas$2.1M
- Manish JhaDallas$1.3M
- Mary KnesevichDallas$1.2M
- Seema GuptaDallas$1.2M
- Eric WilliamsDallas$976K
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.